[Edaily Reporter KIM SAE-MI ] MedPacto, Inc.(235980)announced on the 22nd that it will participate in the “2026 Bio International Convention” (BioUSA), taking place in San Diego, U.S., from the 22nd to the 25th (local time).

BioUSA is a global biotech industry event organized by the U.S. Biotechnology Innovation Organization (BIO). Approximately 20,000 pharmaceutical and biotech professionals from over 80 countries worldwide are expected to attend this year’s event.

At this event, MedPacto, Inc. will hold partnering meetings with global pharmaceutical and biotech companies, research institutions, and investment firms. Through these meetings, the company plans to explore strategic collaboration opportunities, including technology transfer, joint research, and investment attraction.

At BioUSA, MedPacto, Inc. will present the current status of clinical trials for its anti-cancer candidate “Bactosetip” in rare cancers, preclinical results for its new pipeline candidate “MP010,” and future clinical plans. Approximately 50 meetings have been scheduled in advance.

MP010 is a next-generation TGF-β-targeted pipeline that targets the tumor microenvironment (TME). MedPacto, Inc. aims to begin clinical trials for MP010 in the second half of the year and plans to pursue the development of combination therapies with other anticancer drugs, such as antibody-drug conjugates (ADCs), in the future.

A MedPacto, Inc. official stated, “As we have accumulated clinical and preclinical data for each pipeline, we plan to discuss specific collaboration strategies with overseas pharmaceutical companies with whom we have been in ongoing discussions.”

Meanwhile, MedPacto, Inc. was recently selected as a recipient of support under the Korea Drug Development Fund (KDDF)’s “2026 National New Drug Development Project Excellence Program.” As a result, the company will receive financial support for pre-event consulting and registration fees related to its participation in Bio USA.